Literature DB >> 16443003

Characterization of the urinary albumin degradation pathway in the isolated perfused rat kidney.

Lucinda M Hilliard1, Tanya M Osicka, Steven P Clavant, Phillip J Robinson, David J Nikolic-Paterson, Wayne D Comper.   

Abstract

This study examines the existence of the urinary albumin degradation pathway and the proposed role of receptor-mediated endocytosis in this process using the isolated perfused rat kidney (IPK) model. Albumin-derived peptides in IPK urine are analyzed in terms of their relative size distribution using radioactivity and absorbance at 214 nm, and their susceptibility to trypsin digestion. The effects of perfusing kidneys with concanamycin A and myristoyl trimethyl ammonium bromide (MTMAB), inhibitors of the receptor-mediated endocytosis regulators vacuolar-type H(+) ATPase (v-ATPase) and dynamin GTPase, respectively, are examined. Normal IPK urine contains mildly degraded (defined as approximately 10-40 kDa; 43.0 +/- 8.3%) and heavily degraded (defined as <10 kDa; 22.6 +/- 7.7%) albumin peptides as well as intact albumin (34.5 +/- 4.1%). The relative size distribution of the peptides is similar by radioactivity and absorbance at 214 nm, and both profiles are reduced to very small peptides following trypsin digestion. Administration of concanamycin A or MTMAB causes a significant increase in the proportion of intact albumin (concanamycin A: 55.8 +/- 11.6%; MTMAB: 50.0 +/- 11.9%) excreted compared with normal IPK urine. This coincides with a reduction in the proportion of mildly (concanamycin A: 27.6 +/- 9.8%; MTMAB: 39.9 +/- 11.5%) and heavily degraded (concanamycin A: 16.6 +/- 7.4%; MTMAB: 10.0 +/- 2.5%) albumin present and is not associated with changes in glomerular permeability to albumin because no significant change is observed in the fractional clearance of Ficoll (radius range 20-60 A) in the presence of concanamycin A. This study demonstrates the existence of albumin peptides in IPK urine and suggests that receptor-mediated endocytosis plays a role in urinary albumin degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443003     DOI: 10.1016/j.lab.2005.08.008

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

Review 1.  Using 2-photon microscopy to understand albuminuria.

Authors:  Bruce A Molitoris
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

Review 2.  The proximal tubule and albuminuria: really!

Authors:  Landon E Dickson; Mark C Wagner; Ruben M Sandoval; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 10.121

3.  Renal FcRn reclaims albumin but facilitates elimination of IgG.

Authors:  Menaka Sarav; Ying Wang; Bradley K Hack; Anthony Chang; Mark Jensen; Lihua Bao; Richard J Quigg
Journal:  J Am Soc Nephrol       Date:  2009-08-06       Impact factor: 10.121

Review 4.  Where does albuminuria come from in diabetic kidney disease?

Authors:  Wayne D Comper; Leileata M Russo
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

5.  Inhibition of the metabolic degradation of filtered albumin is a major determinant of albuminuria.

Authors:  Julijana Vuchkova; Wayne D Comper
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

6.  Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis.

Authors:  Adam McCluskey; James A Daniel; Gordana Hadzic; Ngoc Chau; Emma L Clayton; Anna Mariana; Ainslie Whiting; Nick N Gorgani; Jonathan Lloyd; Annie Quan; Lia Moshkanbaryans; Sai Krishnan; Swetha Perera; Megan Chircop; Lisa von Kleist; Andrew B McGeachie; Mark T Howes; Robert G Parton; Michael Campbell; Jennette A Sakoff; Xuefeng Wang; Jian-Yuan Sun; Mark J Robertson; Fiona M Deane; Tam H Nguyen; Frederic A Meunier; Michael A Cousin; Phillip J Robinson
Journal:  Traffic       Date:  2013-10-09       Impact factor: 6.215

Review 7.  Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications.

Authors:  Bruce A Molitoris; Ruben M Sandoval; Shiv Pratap S Yadav; Mark C Wagner
Journal:  Physiol Rev       Date:  2022-04-04       Impact factor: 46.500

8.  Biodistribution of Multimodal Gold Nanoclusters Designed for Photoluminescence-SPECT/CT Imaging and Diagnostic.

Authors:  Greta Jarockyte; Marius Stasys; Vilius Poderys; Kornelija Buivydaite; Marijus Pleckaitis; Danute Bulotiene; Marija Matulionyte; Vitalijus Karabanovas; Ricardas Rotomskis
Journal:  Nanomaterials (Basel)       Date:  2022-09-20       Impact factor: 5.719

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.